Corrigendum to “Tensin1 positively regulates RhoA activity through its interaction with DLC1” [Biochimica et Biophysica Acta 1853/12 (2015) 3258–3265] (S0167488915003407) (10.1016/j.bbamcr.2015.09.028));Tensin1 positively regulates RhoA activity through its interaction with DLC1

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 12, 2015, Pages 3258-3265

  Shih, Yi Ping ^a   Sun, Peng ^a   Wang, Aifeng ^a   Lo, Su Hao ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; DLC1; Focal adhesion; RhoA; Tensin

Indexed keywords

DLC1 PROTEIN; FOCAL ADHESION KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; TENSIN1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; DLC-1 (DELETED IN LIVER CANCER) PROTEIN, MOUSE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PROTEIN BINDING; TENSINS;

ACTIN FILAMENT; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; SEQUENCE HOMOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; GTPASE-ACTIVATING PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; MICE; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RHOA GTP-BINDING PROTEIN; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR SUPPRESSOR PROTEINS;

EID: 84943390164     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2018.05.016     Document Type: Erratum

References (25)

1. Homma Y., Emori Y. A dual functional signal mediator showing RhoGAP and phospholipase C-delta stimulating activities. EMBO J. 1995, 14:286-291.
2. Yuan B.Z., Miller M.J., Keck C.L., Zimonjic D.B., Thorgeirsson S.S., Popescu N.C. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998, 58:2196-2199.
3. Liao Y.C., Lo S.H. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int. J. Biochem. Cell Biol. 2008, 40:843-847.
4. Durkin M.E., Yuan B.Z., Zhou X., Zimonjic D.B., Lowy D.R., Thorgeirsson S.S., Popescu N.C. DLC-1: a Rho GTPase-activating protein and tumour suppressor. J. Cell. Mol. Med. 2007, 11:1185-1207.
5. Kim T.Y., Vigil D., Der C.J., Juliano R.L. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev. 2009, 28:77-83.
6. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
7. Liao Y.C., Shih Y.P., Lo S.H. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res. 2008, 68:7718-7722.
8. Narumiya S., Tanji M., Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009, 28:65-76.
9. Lo S.H. Tensin. Int. J. Biochem. Cell Biol. 2004, 36:31-34.
10. Lo S.H., Janmey P.A., Hartwig J.H., Chen L.B. Interactions of tensin with actin and identification of its three distinct actin-binding domains. J. Cell Biol. 1994, 125:1067-1075.
11. Cui Y., Liao Y.C., Lo S.H. Epidermal growth factor modulates tyrosine phosphorylation of a novel tensin family member, tensin3. Mol. Cancer Res.: MCR 2004, 2:225-232.
12. Hafizi S., Alindri F., Karlsson R., Dahlback B. Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. Biochem. Biophys. Res. Commun. 2002, 299:793-800.
13. Davis S., Lu M.L., Lo S.H., Lin S., Butler J.A., Druker B.J., Roberts T.M., An Q., Chen L.B. Presence of an SH2 domain in the actin-binding protein tensin. Science 1991, 252:712-715.
14. Chen H., Duncan I.C., Bozorgchami H., Lo S.H. Tensin1 and a previously undocumented family member, tensin2, positively regulate cell migration. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:733-738.
15. Chen H., Ishii A., Wong W.K., Chen L.B., Lo S.H. Molecular characterization of human tensin. Biochem. J. 2000, 351(Pt 2):403-411.
16. Lo S.H., Lo T.B. Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer. Cancer Res. 2002, 62:4217-4221.
17. Liao Y.C., Si L., Devere White R.W., Lo S.H. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J. Cell Biol. 2007, 176:43-49.
18. Lo S.H., Yu Q.C., Degenstein L., Chen L.B., Fuchs E. Progressive kidney degeneration in mice lacking tensin. J. Cell Biol. 1997, 136:1349-1361.
19. Katz M., Amit I., Citri A., Shay T., Carvalho S., Lavi S., Milanezi F., Lyass L., Amariglio N., Jacob-Hirsch J., Ben-Chetrit N., Tarcic G., Lindzen M., Avraham R., Liao Y.C., Trusk P., Lyass A., Rechavi G., Spector N.L., Lo S.H., Schmitt F., Bacus S.S., Yarden Y. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat. Cell Biol. 2007, 9:961-969.
20. Heering J., Erlmann P., Olayioye M.A. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Exp. Cell Res. 2009, 315:2505-2514.
21. Yam J.W., Ko F.C., Chan C.Y., Jin D.Y., Ng I.O. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 2006, 66:8367-8372.
22. Qian X., Li G., Asmussen H.K., Asnaghi L., Vass W.C., Braverman R., Yamada K.M., Popescu N.C., Papageorge A.G., Lowy D.R. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9012-9017.
23. Cao X., Voss C., Zhao B., Kaneko T., Li S.S. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:1455-1460.
24. Tripathi B.K., Qian X., Mertins P., Wang D., Papageorge A.G., Carr S.A., Lowy D.R. CDK5 is a major regulator of the tumor suppressor DLC1. J. Cell Biol. 2014, 207:627-642.
25. Ravi A., Kaushik S., Ravichandran A., Pan C.Q., Low B.C. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) deleted in liver cancer 1 via focal adhesion kinase and protein phosphatase 2A. J. Biol. Chem. 2015, 290:4149-4162.